Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG039
MIFTS: 66

Lung Squamous Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lung Squamous Cell Carcinoma

About this section

MalaCards integrated aliases for Lung Squamous Cell Carcinoma:

Name: Lung Squamous Cell Carcinoma 12 15
Squamous Cell Carcinoma of Lung 12 71
Squamous Cell Lung Carcinoma 6 17
Epidermoid Cell Carcinoma of the Lung 12
Squamous Cell Lung Cancer 54

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3907
NCIt 49 C3493
SNOMED-CT 67 254634000
UMLS 71 C0149782
Sources

Summaries for Lung Squamous Cell Carcinoma

About this section
Disease Ontology : 12 A non-small cell lung carcinoma that has material basis in the squamous cell.

MalaCards based summary : Lung Squamous Cell Carcinoma, also known as squamous cell carcinoma of lung, is related to squamous cell carcinoma and adenocarcinoma. An important gene associated with Lung Squamous Cell Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are TGF-Beta Pathway and Developmental Biology. The drugs Nedaplatin and Apatinib have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and t cells, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Squamous-cell carcinoma (SCC) of the lung is a histologic type of non-small-cell lung carcinoma (NSCLC).... more...

Sources

Related Diseases for Lung Squamous Cell Carcinoma

About this section

Diseases related to Lung Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 443)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 32.5 TUG1 TP53 SOX2-OT PTEN PIK3CA NFE2L2
2 adenocarcinoma 32.4 TP53 PTEN PIK3CA KRAS HRAS FGFR3
3 lung cancer 32.3 TUG1 TP53 TERC SOX2-OT SNHG1 PVT1
4 lung cancer susceptibility 3 32.2 TUG1 TP53 SFTA1P PTEN PIK3CA NFE2L2
5 small cell carcinoma 31.7 TP53 PTEN KRAS EGFR
6 papilloma 31.5 TP53 PTEN KRAS FGFR3 EGFR
7 in situ carcinoma 31.2 TP53 PTEN PIK3CA HRAS EGFR
8 adenosquamous carcinoma 31.2 TP53 PTEN PIK3CA KRAS EGFR
9 breast adenocarcinoma 31.1 TP53 PIK3CA KRAS EGFR
10 lung adenoma 31.1 TP53 KRAS HRAS EGFR
11 lung benign neoplasm 31.1 TP53 KRAS HRAS EGFR
12 retinitis pigmentosa 11 31.1 TP53 PVT1 PTEN HRAS EGFR
13 large cell carcinoma 31.0 KRAS HRAS EGFR
14 lung carcinoma in situ 31.0 KRAS HRAS EGFR
15 small cell cancer of the lung 31.0 TUG1 TP53 PTEN PIK3CA EGFR
16 thymoma 31.0 TP53 PIK3CA HRAS EGFR
17 lung non-squamous non-small cell carcinoma 31.0 KRAS HRAS EGFR
18 signet ring cell adenocarcinoma 31.0 TP53 KRAS HRAS
19 transitional cell carcinoma 31.0 TP53 PTEN PIK3CA HRAS FGFR3 EGFR
20 cholangiocarcinoma 30.9 TUG1 TP53 SOX2-OT PIK3CA KRAS FGFR2
21 papillary adenocarcinoma 30.9 TP53 KRAS HRAS
22 colorectal adenocarcinoma 30.9 TP53 PTEN KRAS HRAS EGFR BRAF
23 thyroid gland anaplastic carcinoma 30.9 TP53 PTEN PIK3CA HRAS EGFR BRAF
24 exanthem 30.9 KRAS HRAS EGFR
25 lymphoma 30.9 TP53 PVT1 PTPN11 PIK3CA EGFR BRAF
26 glioblastoma multiforme 30.9 TP53 PTEN PIK3CA KRAS HRAS EGFR
27 glioma 30.9 TP53 PVT1 PTEN PIK3CA EGFR BRAF
28 adenoid cystic carcinoma 30.9 TP53 PTEN PIK3CA KRAS HRAS EGFR
29 intrahepatic cholangiocarcinoma 30.9 TUG1 TP53 PTEN KRAS FGFR2 EGFR
30 kidney cancer 30.8 TP53 PVT1 PTEN PIK3CA NFE2L2 EGFR
31 thyroid carcinoma 30.8 PTEN PIK3CA HRAS BRAF
32 squamous cell papilloma 30.8 TP53 HRAS
33 brain glioma 30.8 TP53 PTEN EGFR
34 pancreatic ductal adenocarcinoma 30.8 TP53 PVT1 PTEN KRAS EGFR
35 skin melanoma 30.7 TP53 PTEN HRAS BRAF
36 neuroblastoma 30.7 TP53 SNHG1 PTPN11 PTEN PIK3CA NFE2L2
37 leukemia, chronic lymphocytic 30.7 TP53 PTPN11 PTEN PIK3CA KRAS HRAS
38 nasopharyngeal carcinoma 30.5 TP53 PVT1 PTEN PIK3CA HRAS EGFR
39 melanoma 30.4 TP53 SOX2-OT PVT1 PTEN PIK3CA KRAS
40 renal cell carcinoma, nonpapillary 30.4 TUG1 TP53 PVT1 PTEN PIK3CA HRAS
41 leukemia, acute myeloid 30.3 TUG1 TP53 PTPN11 PTEN PIK3CA KRAS
42 malignant pleural mesothelioma 30.2 TP53 PVT1 EGFR
43 bladder cancer 30.1 TUG1 TP53 TERC PVT1 PTEN PIK3CA
44 myeloma, multiple 30.1 TUG1 TP53 PVT1 PTPN11 PTEN KRAS
45 myelodysplastic syndrome 30.1 TP53 TERC PTPN11 PTEN KRAS HRAS
46 breast cancer 29.9 TUG1 TP53 SOX2-OT PVT1 PTPN11 PTEN
47 gastric cancer 29.7 TUG1 TP53 TERC SOX2-OT SNHG1 SFTA1P
48 hepatocellular carcinoma 29.6 TUG1 TP53 TERC SOX2-OT SNHG1 PVT1
49 lung occult squamous cell carcinoma 11.5
50 lung mixed small cell and squamous cell carcinoma 11.5

Graphical network of the top 20 diseases related to Lung Squamous Cell Carcinoma:



Diseases related to Lung Squamous Cell Carcinoma
Sources

Symptoms & Phenotypes for Lung Squamous Cell Carcinoma

About this section

GenomeRNAi Phenotypes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.4 EGFR HRAS KRAS PIK3CA BRAF
2 Decreased viability GR00055-A-2 10.4 EGFR HRAS KRAS PIK3CA BRAF
3 Decreased viability GR00055-A-3 10.4 KRAS
4 Decreased viability GR00106-A-0 10.4 KRAS
5 Decreased viability GR00221-A-1 10.4 EGFR FGFR3 HRAS KRAS PIK3CA
6 Decreased viability GR00221-A-2 10.4 FGFR3 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.4 FGFR3 HRAS
8 Decreased viability GR00221-A-4 10.4 EGFR PIK3CA BRAF
9 Decreased viability GR00249-S 10.4 FGFR3 BRAF
10 Decreased viability GR00301-A 10.4 KRAS BRAF
11 Decreased viability GR00381-A-1 10.4 KRAS BRAF
12 Decreased viability GR00402-S-2 10.4 PIK3CA
13 Decreased cell migration GR00055-A-1 9.81 FGFR3
14 Decreased cell migration GR00055-A-3 9.81 BRAF EGFR HRAS PIK3CA
15 Reduced mammosphere formation GR00396-S 9.17 BRAF EGFR HRAS KRAS NFE2L2 PTEN

MGI Mouse Phenotypes related to Lung Squamous Cell Carcinoma:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.28 BRAF EGFR FGFR2 HRAS KRAS NFE2L2
2 digestive/alimentary MP:0005381 10.27 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
3 integument MP:0010771 10.26 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
4 craniofacial MP:0005382 10.23 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
5 embryo MP:0005380 10.21 BRAF EGFR FGFR2 KRAS NFE2L2 PIK3CA
6 endocrine/exocrine gland MP:0005379 10.2 BRAF EGFR FGFR2 HRAS KRAS PIK3CA
7 neoplasm MP:0002006 10.2 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
8 adipose tissue MP:0005375 10.19 BRAF EGFR FGFR2 NFE2L2 PIK3CA PTEN
9 nervous system MP:0003631 10.17 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
10 limbs/digits/tail MP:0005371 10.11 BRAF EGFR FGFR2 FGFR3 KRAS PTEN
11 liver/biliary system MP:0005370 10.1 BRAF EGFR FGFR2 KRAS NFE2L2 PTEN
12 hearing/vestibular/ear MP:0005377 10.08 BRAF EGFR FGFR2 FGFR3 KRAS PTPN11
13 muscle MP:0005369 10.08 BRAF EGFR FGFR2 KRAS PIK3CA PTEN
14 normal MP:0002873 10.07 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
15 no phenotypic analysis MP:0003012 10.01 EGFR FGFR2 FGFR3 HRAS KRAS PIK3CA
16 renal/urinary system MP:0005367 9.91 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
17 pigmentation MP:0001186 9.87 BRAF EGFR FGFR2 KRAS PTEN PTPN11
18 respiratory system MP:0005388 9.85 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
19 skeleton MP:0005390 9.7 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
20 vision/eye MP:0005391 9.28 BRAF EGFR FGFR2 FGFR3 KRAS PIK3CA
Sources

Drugs & Therapeutics for Lung Squamous Cell Carcinoma

About this section

Drugs for Lung Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nedaplatin Approved, Investigational Phase 4 95734-82-0
2
Apatinib Phase 4 811803-05-1
3
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
4
Etoposide Approved Phase 3 33419-42-0 36462
5
Osimertinib Approved Phase 2, Phase 3 1421373-65-0 71496458
6
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
7
Vinblastine Approved Phase 3 865-21-4 241903 13342
8
Ipilimumab Approved Phase 3 477202-00-9
9
nivolumab Approved Phase 2, Phase 3 946414-94-4
10
Durvalumab Approved, Investigational Phase 2, Phase 3 1428935-60-7
11
Talazoparib Approved, Investigational Phase 2, Phase 3 1207456-01-6 135565082
12
Palbociclib Approved, Investigational Phase 2, Phase 3 571190-30-2 5005498 11431660 5330286
13
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 54677470 5281106
14
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
15
Pemetrexed Approved, Investigational Phase 3 137281-23-3, 150399-23-8 60843 446556
16
leucovorin Approved Phase 3 58-05-9 6006 143
17
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
18
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
19
Lenograstim Approved, Investigational Phase 3 135968-09-1
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
21
Iniparib Investigational Phase 3 160003-66-7
22
Tirapazamine Investigational Phase 3 27314-97-2
23
Tremelimumab Investigational Phase 2, Phase 3 745013-59-6
24
Rilotumumab Investigational Phase 2, Phase 3 872514-65-3
25 Endostar protein Phase 3
26 Endostatins Phase 3 71581480
27 Etoposide phosphate Phase 3
28 Hematinics Phase 3
29 Epoetin alfa Phase 3 113427-24-0
30 Immunoglobulin G Phase 2, Phase 3
31 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3
32 Pharmaceutical Solutions Phase 2, Phase 3
33 Vaccines Phase 2, Phase 3
34 Immunoglobulins Phase 2, Phase 3
35 Antibodies Phase 2, Phase 3
36 Antibodies, Monoclonal Phase 2, Phase 3
37 Antineoplastic Agents, Immunological Phase 2, Phase 3
38 Vitamin B Complex Phase 3
39 Folic Acid Antagonists Phase 3
40 Folate Phase 3
41 Vitamin B9 Phase 3
42 Immunoglobulins, Intravenous Phase 2, Phase 3
43 Anti-Inflammatory Agents Phase 3
44 Antirheumatic Agents Phase 3
45 Anti-Bacterial Agents Phase 3
46 Angiogenesis Inhibitors Phase 3
47
Erlotinib Hydrochloride Phase 2, Phase 3 183319-69-9 176871
48 Cyclooxygenase 2 Inhibitors Phase 3
49 Analgesics Phase 3
50 Analgesics, Non-Narcotic Phase 3

Interventional clinical trials:

(show top 50) (show all 221)
# Name Status NCT ID Phase Drugs
1 Nedaplatin (Jiebaishu®) and Docetaxel in Comparison With Cisplatin and Docetaxel Regimen for the First Line Treatment of Advanced Squamous Cell Carcinoma of Lung(IIIB/IV): Randomized, Controlled, Multicentre Study Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
2 An Open-label, Single-arm Clinical Study to Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation Recruiting NCT04132102 Phase 4 Afatinib
3 Apatinib Mesylate Was Used in the Treament of Patients With Advanced Lung Squamous Cell Carcinoma of the Third Line and Above Not yet recruiting NCT03725423 Phase 4 Apatinib
4 Evaluation of the Benefits of Oral Metronomic Cyclophosphamide in Combination With Standard Cisplatin-etoposide Based Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
5 Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer :A Randomized, Open, Parallel, Multicentre, Phase â…¢ Study Unknown status NCT02643407 Phase 3 Docetaxel;Nedaplatin;Cisplatin
6 The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration. Unknown status NCT02283476 Phase 3 Endostar continuous intravenous infusion;Endostar routine intravenous infusion;Gemcitabine;Cisplatin
7 A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Nonprogressive on Gefitinib or Erlotinib Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
8 Induction Pemetrexed and Cisplatin Followed by Pemetrexed as Maintenance vs Carboplatin-paclitaxel and Bevacizumab Followed by Bevacizumab as Maintenance:Multicenter Randomized Phase III Study in Patients With Advanced Non-Squamous Non Small-cell Lung Cancer: a Quality of Life Oriented Phase III Trial of the GOIM Unknown status NCT01303926 Phase 3 cisplatin pemetrexed;carboplatin paclitaxel bevacizumab
9 Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) Completed NCT01082549 Phase 3 gemcitabine/carboplatin;gemcitabine/carboplatin plus Iniparib
10 A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient With Resectable Non-Small Cell Lung Carcinoma Completed NCT00003901 Phase 3
11 Phase III Study of Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer Completed NCT02959749 Phase 2, Phase 3 Osimertinib;docetaxel, bevacizumab
12 Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
13 Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient With N0 and N1 (Less Than Hilar) Non-Small Cell Carcinoma Completed NCT00003831 Phase 3
14 A Phase III Trial of Single Versus Fractionated Thoracic Radiation for Palliation of Symptoms in Patients With Non-Small Cell Lung Cancer Completed NCT00003685 Phase 3
15 Single-Agent Versus Combination Chemotherapy in Advanced NSCLC: A CALGB Randomized Trial of Efficacy, Quality of Life, and Cost-Effectiveness Completed NCT00003117 Phase 3 carboplatin;paclitaxel
16 Randomized Phase III Trial Of Carboplatin And Paclitaxel Plus Tirapazamine Versus Carboplatin And Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
17 Concurrent Carboplatin, Paclitaxel, and Radiation Therapy Versus Induction Carboplatin and Paclitaxel Followed by Concurrent Carboplatin, Paclitaxel and Radiation Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase III Trial Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
18 A Phase III Trial of Induction Paclitaxel and Carboplatin Followed By Standard Radiotherapy (64 Gy/7 Weeks) vs. Hyperfractionated Accelerated Radiotherapy (HART 57.6 Gy/2.5 Weeks) For Patients With Unresectable Stage IIIA and IIIB Non-Small Cell Lung Cancer Completed NCT00003235 Phase 3 carboplatin;paclitaxel
19 A LARGE-SCALE TRIAL EVALUATING ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF NON-SMALL CELL LUNG CANCER Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
20 A Randomized Phase III Trial of Erlotinib Versus Docetaxel in Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Who Failed First Line Platinum Based Doublet Chemotherapy Stratified by VeriStrat Good vs VeriStrat Poor Completed NCT01652469 Phase 3 Erlotinib;Docetaxel
21 A Phase III Randomized Trial Evaluating the Effect of Epoetin Alfa (Procrit) on Local Control in Patients Undergoing Concurrent Chemotherapy and Radiation Therapy for Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
22 RANDOMIZED TRIAL OF SURGERY VERSUS RADIOTHERAPY IN PATIENTS WITH STAGE IIIa NON-SMALL CELL LUNG CANCER AFTER A RESPONSE TO INDUCTION-CHEMOTHERAPY Completed NCT00002623 Phase 3 carboplatin;cisplatin
23 A Phase III Comparison Between Concurrent Chemotherapy Plus Radiotherapy and Concurrent Chemotherapy Plus Radiotherapy Followed by Surgical Resection for Stage IIIA (N2) Non-Small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
24 Phase III Study to Evaluate the Optimal Timing of Postoperative Radiotherapy for High Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
25 A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study) Active, not recruiting NCT02785952 Phase 3
26 A Phase II Study of MEDI4736 for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung-Map Sub-Study) Active, not recruiting NCT02766335 Phase 2, Phase 3 Docetaxel
27 A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map) Active, not recruiting NCT02154490 Phase 2, Phase 3 Docetaxel;Erlotinib Hydrochloride;FGFR Inhibitor AZD4547;Palbociclib;Talazoparib;Taselisib
28 Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase 3 Study (ORIENT-3) Active, not recruiting NCT03150875 Phase 3 Docetaxel
29 A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) Active, not recruiting NCT02785939 Phase 2, Phase 3 Docetaxel;Palbociclib
30 A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) Active, not recruiting NCT02965378 Phase 2, Phase 3 Docetaxel;FGFR Inhibitor AZD4547
31 Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly (More Than 70 Years Old) Patients With Advanced Non-small Cell Lung Cancer Active, not recruiting NCT03351361 Phase 3 Nivolumab + Ipilimumab;Chemotherapy
32 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in Non-small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2): A Randomized Prospective Phase III Trial Active, not recruiting NCT00030771 Phase 3 Chemotherapy
33 A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
34 Proteome-based Personalized Immunotherapy of Brain Metastases From Lung Cancer Enrolling by invitation NCT01782287 Phase 2, Phase 3
35 A Randomized Phase III Study of TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer Terminated NCT01282151 Phase 3 Taxotere;Pemetrexed
36 A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-Met Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) Terminated NCT02926638 Phase 2, Phase 3 Erlotinib Hydrochloride
37 A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients With Early Stage Non-Small Cell Lung Cancer Associated With Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
38 A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
39 A Randomized Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, With or Without Thalidomide, in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
40 Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients With Stage IIIA (N2) Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
41 A Randomized, Phase III Multicenter Trial Of Gemcitabine In Combination With Carboplatin Or Paclitaxel Plus Carboplatin In Patients With Metastatic (Stage IIIB, IV) Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
42 A Phase III Randomized, Open-Label Comparative Study of Induction Chemotherapy Followed by Thoracic Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Patients With Locally Advanced Unresectable (Stage IIIA/IIIB) Non-Small Cell Lung Cancer Withdrawn NCT00055887 Phase 3 carboplatin;cisplatin;efaproxiral;gemcitabine hydrochloride;paclitaxel;vinorelbine ditartrate
43 Photodynamic Therapy for the Prevention of Lung Cancer (PEARL) Withdrawn NCT03346304 Phase 2, Phase 3
44 An Open-label, Single-armed Pilot Study to Evaluate the Efficacy of Icotinib in Previously Treated Non/Light-smoking Patients With Squamous Lung Cancer Unknown status NCT02009605 Phase 2 Icotinib
45 Boanmycin Hydrochloride for Injection in Combination With Docetaxel for Patients With Advanced Lung Squamous Cell Carcinoma as Salvage Chemotherapy: a Prospective, Randomized, Parallel and Controlled Clinical Trial Unknown status NCT01660399 Phase 2 Boanmycin;Docetaxel
46 Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage â…¡ B and IIIA Squamous Cell Carcinoma of the Lung: Parallel Control and Single Center Unknown status NCT01872403 Phase 2 nanoparticle albumin-bound paclitaxel/carboplatin
47 A Phase II Trial of Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer After Failure of Platinum Doublet (Except Pemetrexed) Therapy Unknown status NCT01969955 Phase 2 nanoparticle albumin-bound paclitaxel
48 A Phase II Study of Concurrent Nab-Paclitaxel, Carboplatin and Thoracic Radiotherapy in Local Advanced Squamous Cell Lung Cancer Unknown status NCT01494415 Phase 2 Paclitaxel for Injection（Albumin Bound）;carboplatin
49 Phase I Trial of Anti-GPC3 Chimeric T Cells for Subjects With GPC3-Positive Advanced Hepatocellular Carcinoma Unknown status NCT03084380 Phase 1, Phase 2 Fludarabine;Cyclophosphamide
50 Phase II Study of Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin/Cisplatin in Stage â…¡ B and IIIA Non-small Cell Lung Cancer Patients Unknown status NCT02016209 Phase 2 nanoparticle albumin-bound paclitaxel

Search NIH Clinical Center for Lung Squamous Cell Carcinoma

Sources

Genetic Tests for Lung Squamous Cell Carcinoma

About this section
Sources

Anatomical Context for Lung Squamous Cell Carcinoma

About this section

MalaCards organs/tissues related to Lung Squamous Cell Carcinoma:

40
Lung, Lymph Node, T Cells, Brain, Testes, Breast, Endothelial
Sources

Publications for Lung Squamous Cell Carcinoma

About this section

Articles related to Lung Squamous Cell Carcinoma:

(show top 50) (show all 1764)
# Title Authors PMID Year
1
Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. 6 61
6695174 1984
2
A comparison of serum CYFRA 21-1 and SCC Ag in the diagnosis of squamous cell lung carcinoma. 61 54
8882476 1996
3
Contributions and prognostic values of m6 A RNA methylation regulators in non-small-cell lung cancer. 61
32052446 2020
4
CircTIMELESS regulates the proliferation and invasion of lung squamous cell carcinoma cells via the miR-136-5p/ROCK1 axis. 61
31960961 2020
5
Attenuation of the pro-inflammatory signature of lung cancer-derived mesenchymal stromal cells by statins. 61
32418888 2020
6
The diagnostic efficiency of seven autoantibodies in lung cancer. 61
31764214 2020
7
Comprehensive Analysis of Aberrantly Expressed Profiles of lncRNAs and miRNAs with Associated ceRNA Network in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. 61
31898160 2020
8
Leveraging methylation to identify the potential causal genes associated with survival in lung adenocarcinoma and lung squamous cell carcinoma. 61
32537022 2020
9
Prognostic significance of an invasive leader cell-derived mutation cluster on chromosome 16q. 61
32315457 2020
10
Machine learning identifies 10 feature miRNAs for lung squamous cell carcinoma. 61
32298761 2020
11
Genome-wide analysis of prognostic-related lncRNAs, miRNAs and mRNAs forming a competing endogenous RNA network in lung squamous cell carcinoma. 61
32356177 2020
12
EGFR L861Q and CDK4 amplification responding to afatinib combined with palbociclib treatment in a patient with advanced lung squamous cell carcinoma. 61
32345450 2020
13
Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France). 61
32408133 2020
14
Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR-tyrosine kinase inhibitor treatment in patients with non-small cell lung cancer from different ethnic groups. 61
32346412 2020
15
Whole exome sequencing of lung adenocarcinoma and lung squamous cell carcinoma in one individual: A case report. 61
32578383 2020
16
UHRF1 predicts poor prognosis by triggering cell cycle in lung adenocarcinoma. 61
32495469 2020
17
Comparative Analysis of Age- and Gender-Associated Microbiome in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. 61
32498338 2020
18
LINC01133: an emerging tumor-associated long non-coding RNA in tumor and osteosarcoma. 61
32556990 2020
19
Multiple primary malignancies involving lung cancer: a single-center experience. 61
32578517 2020
20
TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival. 61
32545367 2020
21
Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation. 61
32576270 2020
22
Low SCRIB expression in fibroblasts promotes invasion of lung cancer cells. 61
32534038 2020
23
Increased Prostate-Specific Membrane Antigen Uptake in Neurofibromatosis. 61
32332318 2020
24
MIR205HG acts as a ceRNA to expedite cell proliferation and progression in lung squamous cell carcinoma via targeting miR-299-3p/MAP3K2 axis. 61
32513149 2020
25
NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy. 61
32272498 2020
26
Primary lung squamous cell carcinoma and its association with gastric metastasis: A case report and literature review. 61
32212371 2020
27
Long non-coding RNA LINC01116 regulated miR-744-5p/SCN1B axis to exacerbate lung squamous cell carcinoma. 61
32538822 2020
28
Psoas muscle mass in patients undergoing lung cancer surgery: a prognostic difference between squamous cell carcinoma and adenocarcinoma. 61
31955305 2020
29
Prognostic value of AKAP13 methylation and expression in lung squamous cell carcinoma. 61
32208871 2020
30
Circulating markers of cellular immune activation in prediagnostic blood sample and lung cancer risk in the Lung Cancer Cohort Consortium (LC3). 61
31276202 2020
31
Classifying non-small cell lung cancer types and transcriptomic subtypes using convolutional neural networks. 61
32364237 2020
32
Ancestry-specific predisposing germline variants in cancer. 61
32471518 2020
33
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. 61
32461698 2020
34
Clinical implications of chromatin accessibility in human cancers. 61
32405341 2020
35
Clinical Application of Next-generation Sequencing for the Diagnosis of Lung Squamous Cell Carcinoma: Is It Primary or Secondary? 61
32051379 2020
36
H3K27ac-activated LINC00519 promotes lung squamous cell carcinoma progression by targeting miR-450b-5p/miR-515-5p/YAP1 axis. 61
32297697 2020
37
LINC00173.v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression. 61
32473645 2020
38
Abscopal effect induced by modulated radiation therapy and pembrolizumab in a patient with pancreatic metastatic lung squamous cell carcinoma. 61
32391640 2020
39
A Single Enhanced Dual-Energy CT Scan May Distinguish Lung Squamous Cell Carcinoma From Adenocarcinoma During the Venous phase. 61
31447258 2020
40
Identification of Specific Candidate Diagnostic Biomarkers for Lung Squamous Cell Carcinoma Based on Methylation. 61
31486674 2020
41
An 11-lncRNA risk scoring model predicts prognosis of lung squamous cell carcinoma. 61
32495880 2020
42
Multi-omics analysis at epigenomics and transcriptomics levels reveals prognostic subtypes of lung squamous cell carcinoma. 61
32036209 2020
43
Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation. 61
32367600 2020
44
Fibroblast‑derived exosomal microRNA‑369 potentiates migration and invasion of lung squamous cell carcinoma cells via NF1‑mediated MAPK signaling pathway. 61
32467987 2020
45
An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes. 61
32434476 2020
46
Early detection and management of immune-related myocarditis: Experience from a case with advanced squamous cell lung carcinoma. 61
32248072 2020
47
[A Case of Squamous Cell Lung Cancer in an Elderly Patient with Low PD-L1 Expression Effectively Treated with Nab-Paclitaxel(Nab-PTX)plus Carboplatin (CBDCA)plus Pembrolizumab for a Recurrence after Operation]. 61
32408327 2020
48
Characterization of the immune profile of oral tongue squamous cell carcinomas with advancing disease. 61
32383556 2020
49
Cell-type specific tumorigenesis with Ras oncogenes in human lung epithelial cells. 61
32111352 2020
50
Mechanism of lung adenocarcinoma spine metastasis induced by CXCL17. 61
31832986 2020
Sources

Variations for Lung Squamous Cell Carcinoma

About this section

ClinVar genetic disease variations for Lung Squamous Cell Carcinoma:

6 (show top 50) (show all 272) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_001126112.2(TP53):c.832C>A (p.Pro278Thr)SNV Likely pathogenic,drug response 376643 rs17849781 17:7577106-7577106 17:7673788-7673788
2 TP53 NM_001126112.2(TP53):c.730G>A (p.Gly244Ser)SNV Pathogenic 376600 rs1057519989 17:7577551-7577551 17:7674233-7674233
3 TP53 NM_001126112.2(TP53):c.537T>G (p.His179Gln)SNV Pathogenic 376607 rs876660821 17:7578393-7578393 17:7675075-7675075
4 TP53 NM_001126112.2(TP53):c.578A>C (p.His193Pro)SNV Pathogenic 376612 rs786201838 17:7578271-7578271 17:7674953-7674953
5 PIK3CA NM_006218.4(PIK3CA):c.2176G>A (p.Glu726Lys)SNV Pathogenic 376476 rs867262025 3:178938934-178938934 3:179221146-179221146
6 TP53 NM_001126112.2(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
7 TP53 NM_001126112.2(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
8 TP53 NM_001126112.2(TP53):c.523C>G (p.Arg175Gly)SNV Pathogenic 376649 rs138729528 17:7578407-7578407 17:7675089-7675089
9 TP53 NM_001126112.2(TP53):c.818G>T (p.Arg273Leu)SNV Pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
10 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln)SNV Pathogenic 7829 rs121909229 10:89692905-89692905 10:87933148-87933148
11 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
12 TP53 NM_001126112.2(TP53):c.733G>T (p.Gly245Cys)SNV Pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
13 TP53 NM_001126112.2(TP53):c.725G>A (p.Cys242Tyr)SNV Pathogenic 12354 rs121912655 17:7577556-7577556 17:7674238-7674238
14 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
15 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
16 TP53 NM_001126112.2(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
17 KRAS NM_033360.4(KRAS):c.34G>C (p.Gly12Arg)SNV Pathogenic 12579 rs121913530 12:25398285-25398285 12:25245351-25245351
18 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
19 FGFR2 NM_000141.5(FGFR2):c.870G>C (p.Trp290Cys)SNV Pathogenic 13281 rs121918499 10:123279562-123279562 10:121520048-121520048
20 PTPN11 NM_002834.4(PTPN11):c.226G>A (p.Glu76Lys)SNV Pathogenic 13336 rs121918464 12:112888210-112888210 12:112450406-112450406
21 PTPN11 NM_002834.5(PTPN11):c.227A>G (p.Glu76Gly)SNV Pathogenic 13338 rs121918465 12:112888211-112888211 12:112450407-112450407
22 PTPN11 NM_002834.4(PTPN11):c.227A>C (p.Glu76Ala)SNV Pathogenic 13339 rs121918465 12:112888211-112888211 12:112450407-112450407
23 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
24 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
25 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
26 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
27 BRAF NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg)SNV Pathogenic 13970 rs121913357 7:140481403-140481403 7:140781603-140781603
28 BRAF NM_001374258.1(BRAF):c.1526G>C (p.Gly509Ala)SNV Pathogenic 13971 rs121913355 7:140481402-140481402 7:140781602-140781602
29 BRAF NM_001374258.1(BRAF):c.1526G>A (p.Gly509Glu)SNV Pathogenic 13974 rs121913355 7:140481402-140481402 7:140781602-140781602
30 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
31 FGFR3 NM_001163213.1(FGFR3):c.742C>T (p.Arg248Cys)SNV Pathogenic 16332 rs121913482 4:1803564-1803564 4:1801837-1801837
32 FGFR3 NM_001163213.1(FGFR3):c.746C>G (p.Ser249Cys)SNV Pathogenic 16339 rs121913483 4:1803568-1803568 4:1801841-1801841
33 PIK3CA NM_006218.4(PIK3CA):c.1258T>C (p.Cys420Arg)SNV Pathogenic 31945 rs121913272 3:178927980-178927980 3:179210192-179210192
34 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
35 BRAF NM_001374258.1(BRAF):c.1526G>T (p.Gly509Val)SNV Pathogenic 44803 rs121913355 7:140481402-140481402 7:140781602-140781602
36 EGFR NM_005228.5(EGFR):c.2303G>T (p.Ser768Ile)SNV Pathogenic 45251 rs121913465 7:55249005-55249005 7:55181312-55181312
37 TP53 NM_001126112.2(TP53):c.488A>G (p.Tyr163Cys)SNV Pathogenic 127814 rs148924904 17:7578442-7578442 17:7675124-7675124
38 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
39 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
40 TP53 NM_001126112.2(TP53):c.422G>A (p.Cys141Tyr)SNV Pathogenic 140801 rs587781288 17:7578508-7578508 17:7675190-7675190
41 TP53 NM_001126112.2(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
42 TP53 NM_001126112.2(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
43 PTEN NM_000314.7(PTEN):c.389G>C (p.Arg130Pro)SNV Pathogenic 142018 rs121909229 10:89692905-89692905 10:87933148-87933148
44 TP53 NM_001126112.2(TP53):c.706T>G (p.Tyr236Asp)SNV Pathogenic 142183 rs587782289 17:7577575-7577575 17:7674257-7674257
45 TP53 NM_001126112.2(TP53):c.374C>A (p.Thr125Lys)SNV Pathogenic 216465 rs786201057 17:7579313-7579313 17:7675995-7675995
46 TP53 NM_001126112.2(TP53):c.743G>T (p.Arg248Leu)SNV Pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
47 TP53 NM_001126112.2(TP53):c.743G>C (p.Arg248Pro)SNV Pathogenic 237954 rs11540652 17:7577538-7577538 17:7674220-7674220
48 PTEN NM_001304718.2(PTEN):c.-363C>GSNV Pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
49 PIK3CA NM_006218.4(PIK3CA):c.1357G>A (p.Glu453Lys)SNV Pathogenic 376470 rs1057519925 3:178928079-178928079 3:179210291-179210291
50 NFE2L2 NM_006164.5(NFE2L2):c.235G>A (p.Glu79Lys)SNV Pathogenic/Likely pathogenic 376466 rs1057519922 2:178098810-178098810 2:177234082-177234082

Cosmic variations for Lung Squamous Cell Carcinoma:

9 (show top 50) (show all 46804)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263727 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 24
2 COSM87596300 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.3177G>C p.V1059= 2:135200405-135200405 24
3 COSM92052275 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1662G>T p.L554F 7:89334644-89334644 24
4 COSM92062218 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1610A>G p.K537R 7:89334592-89334592 24
5 COSM92044981 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.983A>G p.N328S 7:89333965-89333965 24
6 COSM92017258 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.743G>A p.C248Y 7:89333725-89333725 24
7 COSM92016873 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.232G>C p.D78H 7:89218278-89218278 24
8 COSM92047471 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.3484C>T p.Q1162* 7:89336466-89336466 24
9 COSM88573896 ZNF804A lung,NS,carcinoma,squamous cell carcinoma c.163G>T p.A55S 2:184866420-184866420 24
10 COSM137961812 ZNF598 lung,NS,carcinoma,squamous cell carcinoma c.386G>A p.R129H 16:2002647-2002647 24
11 COSM94776745 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.934T>A p.C312S 18:25226984-25226984 24
12 COSM94799739 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.1417C>T p.P473S 18:25226501-25226501 24
13 COSM90068315 ZNF479 lung,NS,carcinoma,squamous cell carcinoma c.1064G>T p.C355F 7:57120351-57120351 24
14 COSM86289413 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 24
15 COSM85262562 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 24
16 COSM85263435 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 24
17 COSM143112283 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 24
18 COSM143104196 ZMYM2 lung,NS,carcinoma,squamous cell carcinoma c.1484G>T p.C495F 13:20006558-20006558 24
19 COSM143112460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 24
20 COSM143103178 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 24
21 COSM129142258 ZIC4 lung,NS,carcinoma,squamous cell carcinoma c.747G>A p.T249= 3:147395943-147395943 24
22 COSM85617592 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.138C>T p.A46= 3:147410250-147410250 24
23 COSM85619505 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.99G>T p.V33= 3:147410211-147410211 24
24 COSM85617600 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.587G>A p.G196D 3:147410699-147410699 24
25 COSM85618817 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.244C>T p.H82Y 3:147410356-147410356 24
26 COSM85617734 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.430C>G p.P144A 3:147410542-147410542 24
27 COSM85619514 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.979A>T p.T327S 3:147411091-147411091 24
28 COSM85618249 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.64C>A p.H22N 3:147410176-147410176 24
29 COSM127411056 ZFHX4 lung,NS,carcinoma,squamous cell carcinoma c.2919G>T p.L973= 8:76707874-76707874 24
30 COSM149303773 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 24
31 COSM149282130 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.6884A>T p.Q2295L 16:72795798-72795798 24
32 COSM149318853 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.331G>A p.E111K 16:72959815-72959815 24
33 COSM149318882 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 24
34 COSM149268808 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 24
35 COSM149260552 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10961C>T p.S3654L 16:72787315-72787315 24
36 COSM149316595 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.4628G>A p.R1543H 16:72798054-72798054 24
37 COSM149303017 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 24
38 COSM149309579 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 24
39 COSM149263533 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1910G>A p.G637E 16:72958236-72958236 24
40 COSM149322707 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 24
41 COSM149308605 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.1724A>C p.E575A 16:72958422-72958422 24
42 COSM149327483 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1582C>T p.Q528* 16:72958564-72958564 24
43 COSM149265687 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8982C>G p.F2994L 16:72793700-72793700 24
44 COSM149269636 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 24
45 COSM149263422 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 24
46 COSM149332384 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.1513G>T p.D505Y 16:72958633-72958633 24
47 COSM149290601 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10628C>A p.A3543D 16:72787648-72787648 24
48 COSM149305555 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1408G>T p.E470* 16:72958738-72958738 24
49 COSM149259619 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.1282A>T p.T428S 16:72958864-72958864 24
50 COSM149259608 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10766C>G p.S3589C 16:72787510-72787510 24

Copy number variations for Lung Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 61)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13957 1 101664084 102994090 Loss COL11A1 Lung squamous cell carcinoma
2 18603 1 146800000 147200000 Loss LOC645166 Lung squamous cell carcinoma
3 18604 1 146800000 147200000 Loss NBPF15 Lung squamous cell carcinoma
4 18605 1 146800000 147200000 Loss NBPF16 Lung squamous cell carcinoma
5 18606 1 146800000 147200000 Loss PPIAL4E Lung squamous cell carcinoma
6 47066 10 89540134 89615643 Loss PTEN Lung squamous cell carcinoma
7 51887 11 132926079 134452384 Loss ACAD8 Lung squamous cell carcinoma
8 58625 11 68821296 70110392 Gain CCND1 Lung squamous cell carcinoma
9 58626 11 68821296 70110392 Gain PPFIA1 Lung squamous cell carcinoma
10 79487 13 72396304 72490843 Loss Lung squamous cell carcinoma
11 89148 15 100100000 100300000 Loss OR4F15 Lung squamous cell carcinoma
12 89149 15 100100000 100300000 Loss OR4F4 Lung squamous cell carcinoma
13 89150 15 100100000 100300000 Loss OR4F6 Lung squamous cell carcinoma
14 105616 16 80626349 81449546 Loss Lung squamous cell carcinoma
15 107157 17 12394069 12459756 Loss Lung squamous cell carcinoma
16 118123 17 7571720 7590868 Mutation TP53 Lung squamous cell carcinoma
17 122933 18 64017241 75522477 Loss CD226 Lung squamous cell carcinoma
18 122934 18 64017241 75522477 Loss MBP Lung squamous cell carcinoma
19 122935 18 64017241 75522477 Loss RTTN Lung squamous cell carcinoma
20 122936 18 64017241 75522477 Loss SOCS6 Lung squamous cell carcinoma
21 128995 19 43840068 44336812 Gain AKT2 Lung squamous cell carcinoma
22 128996 19 43840068 44336812 Gain ECH1 Lung squamous cell carcinoma
23 130187 19 47900000 48300000 Loss PSG1 Lung squamous cell carcinoma
24 130188 19 47900000 48300000 Loss PSG11 Lung squamous cell carcinoma
25 130189 19 47900000 48300000 Loss PSG2 Lung squamous cell carcinoma
26 130190 19 47900000 48300000 Loss PSG3 Lung squamous cell carcinoma
27 130191 19 47900000 48300000 Loss PSG6 Lung squamous cell carcinoma
28 130192 19 47900000 48300000 Loss PSG7 Lung squamous cell carcinoma
29 130193 19 47900000 48300000 Loss PSG8 Lung squamous cell carcinoma
30 131640 19 55600000 55700000 Gain ASPDH Lung squamous cell carcinoma
31 131641 19 55600000 55700000 Gain C19orf63 Lung squamous cell carcinoma
32 131642 19 55600000 55700000 Gain FAM71E1 Lung squamous cell carcinoma
33 131643 19 55600000 55700000 Gain JOSD2 Lung squamous cell carcinoma
34 131644 19 55600000 55700000 Gain MYBPC2 Lung squamous cell carcinoma
35 131645 19 55600000 55700000 Gain NAPSA Lung squamous cell carcinoma
36 131646 19 55600000 55700000 Gain NR1H2 Lung squamous cell carcinoma
37 131647 19 55600000 55700000 Gain POLD1 Lung squamous cell carcinoma
38 131648 19 55600000 55700000 Gain SPIB Lung squamous cell carcinoma
39 149556 11 35116992 35210525 Loss IN Lung squamous cell carcinoma
40 149667 2 91000000 91500000 Loss GGT8P Lung squamous cell carcinoma
41 149668 2 91000000 91500000 Loss LOC654342 Lung squamous cell carcinoma
42 172539 3 183473858 183941579 Gain SOX2 Lung squamous cell carcinoma
43 172540 3 183473858 183941579 Gain TP73L Lung squamous cell carcinoma
44 179006 3 84414538 85858393 Loss POU1F1 Lung squamous cell carcinoma
45 181932 4 130278523 134426567 Loss PLK4 Lung squamous cell carcinoma
46 185649 4 20391110 20848036 Loss BST1 Lung squamous cell carcinoma
47 185650 4 20391110 20848036 Loss PI4K2B Lung squamous cell carcinoma
48 185651 4 20391110 20848036 Loss SLIT2 Lung squamous cell carcinoma
49 191445 5 1 1510601 Gain TERT Lung squamous cell carcinoma
50 202010 5 76066702 76539988 Loss HTR1A Lung squamous cell carcinoma
Sources

Expression for Lung Squamous Cell Carcinoma

About this section
Search GEO for disease gene expression data for Lung Squamous Cell Carcinoma.
Sources

Pathways for Lung Squamous Cell Carcinoma

About this section

Pathways related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 119)
# Super pathways Score Top Affiliating Genes
1
TGF-Beta Pathway 63
Show member pathways
 13.65 TP53 PTPN11 PIK3CA KRAS HRAS FGFR3
2
Developmental Biology 65
Show member pathways
 13.6 PTPN11 PIK3CA KRAS HRAS FGFR3 FGFR2
3
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.55 TP53 PTPN11 PTEN PIK3CA KRAS HRAS
4
Cytokine Signaling in Immune system 65
Show member pathways
 13.47 TP53 PTPN11 PIK3CA KRAS HRAS FGFR3
5
PAK Pathway 63
Show member pathways
 13.39 PTPN11 PTEN KRAS HRAS FGFR3 FGFR2
6
GAB1 signalosome 65
Show member pathways
 13.22 TP53 PTPN11 PTEN PIK3CA FGFR3 FGFR2
7
Phospholipase-C Pathway 63
Show member pathways
 13.17 TP53 PTEN KRAS HRAS FGFR3 FGFR2
8
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.15 TP53 PIK3CA KRAS HRAS EGFR BRAF
9
PI3K-Akt signaling pathway 36
Show member pathways
 13.08 TP53 PTEN PIK3CA KRAS HRAS FGFR3
10
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13.02 PTPN11 PTEN PIK3CA KRAS HRAS EGFR
11
Focal Adhesion 36 1
Show member pathways
 13.01 PTEN PIK3CA KRAS HRAS EGFR BRAF
12
Downstream signaling of activated FGFR2 65
Show member pathways
 12.97 PTPN11 PIK3CA KRAS HRAS FGFR3 FGFR2
13
NFAT and Cardiac Hypertrophy 63
Show member pathways
 12.96 PTEN PIK3CA KRAS HRAS FGFR3 FGFR2
14
Development Angiotensin activation of ERK 22
Show member pathways
 12.93 PIK3CA KRAS HRAS EGFR BRAF
15
Endometrial cancer 36
Show member pathways
 12.91 TP53 PTPN11 PTEN PIK3CA KRAS HRAS
16
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.89 PTPN11 PTEN PIK3CA KRAS HRAS BRAF
17
MAPK signaling pathway 36 1
12.87 TP53 KRAS HRAS FGFR3 FGFR2 EGFR
18
Development HGF signaling pathway 22
Show member pathways
 12.82 TP53 PTPN11 PTEN PIK3CA KRAS HRAS
19
Ras signaling pathway 36
Show member pathways
 12.81 PTPN11 PIK3CA KRAS HRAS FGFR3 FGFR2
20
4-1BB Pathway 63
Show member pathways
 12.77 TP53 KRAS HRAS EGFR BRAF
21
Glioma 36
Show member pathways
 12.75 TP53 PTEN PIK3CA KRAS HRAS FGFR2
22
Regulation of actin cytoskeleton 36 1
12.74 PIK3CA KRAS HRAS FGFR3 FGFR2 EGFR
23
T cell receptor signaling pathway 36
Show member pathways
 12.73 PTPN11 PTEN PIK3CA KRAS HRAS EGFR
24
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.73 TP53 PTPN11 PTEN PIK3CA KRAS HRAS
25
Immune response IL-23 signaling pathway 22
Show member pathways
 12.71 TP53 PTPN11 PIK3CA KRAS HRAS EGFR
26
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.69 PTPN11 PTEN PIK3CA KRAS HRAS
27
Gastric cancer 36
Show member pathways
 12.69 TP53 TERC PTEN PIK3CA NFE2L2 KRAS
28
Negative regulation of FGFR3 signaling 65
Show member pathways
 12.66 PTPN11 PIK3CA KRAS HRAS FGFR3 FGFR2
29
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.63 PTPN11 PIK3CA KRAS HRAS BRAF
30
MicroRNAs in cancer 36
12.63 TP53 PTEN PIK3CA KRAS HRAS FGFR3
31
Prolactin Signaling Pathway 36 1
Show member pathways
 12.6 PTPN11 PTEN PIK3CA KRAS HRAS
32
JAK-STAT signaling pathway 36
Show member pathways
 12.56 PTPN11 PIK3CA KRAS HRAS EGFR
33
B Cell Receptor Signaling Pathway (sino) 66
Show member pathways
 12.56 PTPN11 PTEN PIK3CA KRAS HRAS
34
VEGF Signaling 66
Show member pathways
 12.54 TP53 PTEN PIK3CA KRAS HRAS FGFR3
35
Apoptosis Pathway 70
Show member pathways
 12.53 TP53 PIK3CA KRAS HRAS FGFR3 FGFR2
36
Phospholipase D signaling pathway 36
Show member pathways
 12.52 PTPN11 PIK3CA KRAS HRAS EGFR
37
B cell receptor signaling pathway (KEGG) 36
Show member pathways
 12.52 PTPN11 PTEN PIK3CA KRAS HRAS BRAF
38
Development FGFR signaling pathway 22
Show member pathways
 12.52 PTPN11 PIK3CA KRAS HRAS FGFR3 FGFR2
39
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.51 PTPN11 PIK3CA KRAS HRAS BRAF
40
Development IGF-1 receptor signaling 22
Show member pathways
 12.51 TP53 PTPN11 PTEN PIK3CA HRAS
41
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.51 PIK3CA KRAS HRAS FGFR3 FGFR2 EGFR
42
mTOR signalling 65
Show member pathways
 12.49 PTPN11 PIK3CA FGFR3 FGFR2
43
Endocytosis 36
12.49 HRAS FGFR3 FGFR2 EGFR
44
RhoGDI Pathway 63
Show member pathways
 12.47 HRAS FGFR3 FGFR2 EGFR
45
Human T-cell leukemia virus 1 infection 36
12.46 TP53 PTEN PIK3CA KRAS HRAS
46
Development EGFR signaling pathway 22
Show member pathways
 12.44 PIK3CA KRAS HRAS EGFR BRAF
47
Translation Non-genomic (rapid) action of Androgen Receptor 22
Show member pathways
 12.43 TP53 PTEN PIK3CA HRAS EGFR
48
Pathways in cancer 36
12.42 TP53 TERC PTEN PIK3CA NFE2L2 KRAS
49
Signaling by ERBB2 65
Show member pathways
 12.41 PIK3CA KRAS HRAS EGFR
50
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.41 TP53 PTPN11 KRAS HRAS EGFR BRAF
Sources

GO Terms for Lung Squamous Cell Carcinoma

About this section

Biological processes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 PTEN KRAS HRAS FGFR3 FGFR2 EGFR
2 positive regulation of gene expression GO:0010628 9.88 TP53 PTEN NFE2L2 KRAS HRAS BRAF
3 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.8 PIK3CA EGFR BRAF
4 negative regulation of neuron apoptotic process GO:0043524 9.8 PIK3CA KRAS HRAS BRAF
5 fibroblast growth factor receptor signaling pathway GO:0008543 9.78 PTPN11 FGFR3 FGFR2
6 peptidyl-tyrosine phosphorylation GO:0018108 9.78 FGFR3 FGFR2 EGFR BRAF
7 positive regulation of kinase activity GO:0033674 9.77 FGFR3 FGFR2 EGFR
8 Ras protein signal transduction GO:0007265 9.77 TP53 KRAS HRAS
9 cellular response to hypoxia GO:0071456 9.76 TP53 TERC PTEN NFE2L2
10 positive regulation of epithelial cell proliferation GO:0050679 9.74 HRAS FGFR2 EGFR
11 positive regulation of MAP kinase activity GO:0043406 9.73 KRAS HRAS EGFR
12 liver development GO:0001889 9.67 PIK3CA KRAS HRAS EGFR
13 positive regulation of protein kinase B signaling GO:0051897 9.65 PTPN11 PIK3CA FGFR3 FGFR2 EGFR
14 organ growth GO:0035265 9.62 PTPN11 FGFR2
15 cellular response to drug GO:0035690 9.62 TP53 NFE2L2 EGFR BRAF
16 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.61 TP53 EGFR
17 positive regulation of phospholipase activity GO:0010518 9.58 FGFR3 FGFR2
18 endochondral bone growth GO:0003416 9.58 FGFR3 FGFR2
19 regulation of axon regeneration GO:0048679 9.55 PTEN BRAF
20 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.54 TP53 NFE2L2
21 response to isolation stress GO:0035900 9.52 KRAS HRAS
22 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.51 TP53 NFE2L2
23 epidermal growth factor receptor signaling pathway GO:0007173 9.46 PTPN11 PIK3CA EGFR BRAF
24 MAPK cascade GO:0000165 9.43 KRAS HRAS FGFR3 FGFR2 EGFR BRAF
25 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.17 PTPN11 PTEN HRAS FGFR3 FGFR2 EGFR

Molecular functions related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex binding GO:0044877 9.55 TERC KRAS HRAS EGFR BRAF
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 FGFR3 FGFR2 EGFR
3 insulin receptor substrate binding GO:0043560 9.32 PTPN11 PIK3CA
4 fibroblast growth factor-activated receptor activity GO:0005007 8.96 FGFR3 FGFR2
5 protein tyrosine kinase activity GO:0004713 8.92 FGFR3 FGFR2 EGFR BRAF
Sources

Sources for Lung Squamous Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....